Abstract
Cancer is a broad term for many disparate diseases with different etiologies, commonly classified by affected organ site. This review summarizes the published evidence from prospective cohort studies examining the associations between vitamin D, measured as serum 25-hydroxyvitamin D (25OHD) concentrations, and the risk of rarer cancer sites including pancreatic, non-Hodgkin lymphoma, ovarian, endometrial, kidney, gastric and esophageal cancer. Overall, evidence from prospective cohort studies provides little support for a protective association between adequate or higher serum 25OHD concentrations and risk of these rarer cancer sites. Additionally, controversy persists concerning a potential increased risk of pancreatic cancer associated with serum 25OHD levels >100 nmol/L due to conflicting results reported by two large prospective pooling projects.
Keywords: 25-hydroxyvitamin D, Bladder cancer, Cancer, Cohort, Endometrial cancer, Esophageal cancer, Gastric cancer, Kidney cancer, Nested case-control study, Non-Hodgkin lymphoma, Ovarian cancer, Pancreatic cancer, Prospective studies, Vitamin D
Anti-Cancer Agents in Medicinal Chemistry
Title:Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers
Volume: 13 Issue: 1
Author(s): Kathy J. Helzlsouer and Lisa Gallicchio
Affiliation:
Keywords: 25-hydroxyvitamin D, Bladder cancer, Cancer, Cohort, Endometrial cancer, Esophageal cancer, Gastric cancer, Kidney cancer, Nested case-control study, Non-Hodgkin lymphoma, Ovarian cancer, Pancreatic cancer, Prospective studies, Vitamin D
Abstract: Cancer is a broad term for many disparate diseases with different etiologies, commonly classified by affected organ site. This review summarizes the published evidence from prospective cohort studies examining the associations between vitamin D, measured as serum 25-hydroxyvitamin D (25OHD) concentrations, and the risk of rarer cancer sites including pancreatic, non-Hodgkin lymphoma, ovarian, endometrial, kidney, gastric and esophageal cancer. Overall, evidence from prospective cohort studies provides little support for a protective association between adequate or higher serum 25OHD concentrations and risk of these rarer cancer sites. Additionally, controversy persists concerning a potential increased risk of pancreatic cancer associated with serum 25OHD levels >100 nmol/L due to conflicting results reported by two large prospective pooling projects.
Export Options
About this article
Cite this article as:
J. Helzlsouer Kathy and Gallicchio Lisa, Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1871520611307010065
DOI https://dx.doi.org/10.2174/1871520611307010065 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Retraction Notice: The Benefits and Risks of Different Therapies in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
Current Drug Safety Predictive Factors for the Care and Control of Hypertension Based on the Health Belief Model Among Hypertensive Patients During the COVID-19 Epidemic in Sirjan, Iran
Current Hypertension Reviews Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Current and Emerging Therapies in Primary Myelofibrosis
Cardiovascular & Hematological Disorders-Drug Targets Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth,Angiogenesis and Metastasis
Current Pharmaceutical Design Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Food and Gastroesophageal Reflux Disease
Current Medicinal Chemistry Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Metallothioneins and Cancer
Current Protein & Peptide Science CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment
Current Pharmaceutical Design